Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LeonaBio, Inc. (LONA)

LeonaBio warrants become exercisable, could bring $146.2 million if fully exercised by Oct. 19

Neutral Impact 3 of 5 financing Written later

LeonaBio disclosed that its Series A Common Warrants, issued in December 2025 in a private placement, became exercisable on September 18, 2026 and remain exercisable until October 19, 2026. If all warrants are exercised for cash, the company would receive approximately $146.2 million, but the filing warns that some may expire unexercised or be exercised on a cashless basis if the resale registration statement is not effective, which would bring in less or no cash.

Key points

  • Warrants cover 23,031,494 common shares at an exercise price of $6.35 per share.
  • Warrants became exercisable September 18, 2026 and expire to exercise after October 19, 2026.
  • Full cash exercise would provide approximately $146.2 million of additional capital.

The filing

CompanyLeonaBio, Inc. (LONA)
Form8-K, current report
Filed with the SECSep 22, 2026, 4:20 PM ET
Accession number0001193125-26-397952

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.